Sectoral Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Sectoral Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,058	Closed	-$113K	–	70
2019 Q2	$113K	Hold	10,058	–	–	0.01%	82
2019 Q1	$108K	Hold	10,058	–	–	0.01%	97
2018 Q4	$152K	Hold	10,058	–	–	0.02%	89
2018 Q3	$186K	Buy	+10,058	New	+$229K	0.02%	141

Other funds holding CTMX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sectoral Asset Management's CTMX Position: Q3 2019 in Review

Sectoral Asset Management sold out of CytomX Therapeutics (CTMX) in Q3 2019, closing a stake of 10,058 shares — an estimated $113K sold.

Sectoral Asset Management first reported a position in CTMX in Q3 2018 and held it in 4 quarters. The position peaked at $186K in Q3 2018. 113 funds tracked by Wall St. Rank hold CTMX as of Q3 2019.

Sectoral Asset Management reported no remaining CytomX Therapeutics position as of Q3 2019 after selling out during the quarter.
Sectoral Asset Management sold 10,058 CytomX Therapeutics shares in Q3 2019, an estimated $113K.
Sectoral Asset Management first reported a position in CytomX Therapeutics in Q3 2018 and held it in 4 quarters.
Sectoral Asset Management's CytomX Therapeutics position peaked at $186K in Q3 2018.
113 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2019.

Based on Sectoral Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.